Radiopharm Theranostics Ltd (RADX) Research & Development (2023 - 2026)

Radiopharm Theranostics (RADX) has reported Research & Development for 4 consecutive years, with $613449.5 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development rose 102.23% year-over-year to $613449.5 in Q2 2026; TTM through Jun 2026 was -$72.6 million, a N/A change from a year earlier, with the FY2026 full-year figure at $3.0 million, up 111.07% from the prior year.
• Research & Development was $613449.5 for Q2 2026 at Radiopharm Theranostics, up from -$27.5 million in the prior quarter.
• Over five years, Research & Development peaked at $613449.5 in Q2 2026 and troughed at -$27.5 million in Q2 2025.
• A 4-year average of -$18.2 million and a median of -$22.9 million in 2023 frame the typical range for Research & Development.
• Across the five-year window, Research & Development slipped 19.18% in 2025 and soared 102.23% in 2026, its largest moves.
• Over 4 years, Research & Development stood at -$22.6 million in 2023, then fell by 2.01% to -$23.1 million in 2024, then slipped by 19.18% to -$27.5 million in 2025, then soared by 102.23% to $613449.5 in 2026.
• The last three Research & Development figures came in at $613449.5 (Q2 2026), -$27.5 million (Q2 2025), and -$23.1 million (Q2 2024), per Business Quant data.